Research in mice suggests that a gene associated with longevity in humans could help rejuvenate the aging heart and improve cardiovascular health.
Category: life extension – Page 159
In a study from the University of Auckland, scientists found a drug that can increase life span. The age-old quest for immortality has taken a step forward. The team that long-term treatment of healthy mice from middle age (one year) with a drug currently used to treat cancer can increase their lifespan by an average of 10% to around three years.
Epigenetic Leaderboard The Rejuvenation Olympics – where you win by never crossing the finish line See How You Rank Top 15 largest age reversals validated by phenotypically trained epigenetic methylation algorithms Rank Name % Improved From Baseline Chronological Age Baseline PACE PACE Of Aging Now (Mean Of 3 Tests) Managing Doctor 1 Bryan […].
Researchers from Harvard Medical School found that it is the changes that affect the expression of the DNA — called epigenetics — that affect aging. The discovery may pave the way for more insights into how humans age.
The last few years have exceeded all expectations in terms of investment activity in longevity, but much more is needed to push the field forward. With more than 40 investments in the longevity field over the past three years, LongevityTech.fund is one of the world’s most active longevity investment funds. The fund’s wide-ranging investment portfolio includes companies like BrainKey, Gerostate Alpha and Occuity.
LongevityTech.fund is now accepting new investors for its second fund, with a target fund size of $50 million up to a maximum of $100 million USD.
Longevity. Technology: LongevityTech.fund has built an impressive company portfolio that has seen no failures to date, with one IPO (longevity biotech Genflow Biosciences) and one company (longevity risk management firm Vesttoo) recently becoming the fund’s first unicorn (valued at more than $1 billion). To learn more about his views on the longevity market, we spoke to serial entrepreneur and investor Petr Sramek, LongevityTech.fund’s co-founder and managing partner.